Research programme: Rett syndrome therapeutics - Recursion Pharmaceuticals
Latest Information Update: 17 Nov 2014
At a glance
- Originator Recursion Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Rett syndrome
Most Recent Events
- 09 Jul 2014 Early research in Rett syndrome in USA (unspecified route)